SCG 101
Alternative Names: Hepatitis B virus TCR T-cell therapy - SCG Cell Therapy; SCG-101Latest Information Update: 03 Jun 2025
At a glance
- Originator SCG Cell Therapy
- Developer Peking Union Medical College Hospital; SCG Cell Therapy
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Liver cancer
Most Recent Events
- 14 Nov 2024 Efficacy and adverse events data from phase I clinical trials in Liver cancer presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)
- 07 Jun 2024 Updated efficacy data from a phase I trial in Liver cancer released by SCG Cell Therapy
- 05 Jun 2024 Updated efficacy, adverse event and pharmacodynamics data from a phase I trial in Liver cancer presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)